Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mylan Inc has announced that its subsidiary Mylan Pharmaceuticals Inc has received final approval from the FDA for its abbreviated new drug application for Carbidopa and Levodopa orally disintegrating tablets, 10mg/100mg, 25mg/100mg and 25mg/250mg.
Subscribe to our email newsletter
Carbidopa and Levodopa orally disintegrating tablets (ODT), indicated for the treatment of idiopathic Parkinson’s disease, are the generic version of Schwarz Pharma’s Parcopa ODT.
This product, which Mylan has already started to ship, will be the first generic version of Parcopa to reach the market. Currently, Mylan has 110 abbreviated new drug applications pending FDA approval, 23 of which are potential first-to-file opportunities.